{"id":"enoxa","rwe":[{"pmid":"39757753","year":"2025","title":"Polycationic γ-Cyclodextrin with Amino Side Chains for a Highly Efficient Anti-Heparin Coagulant.","finding":"","journal":"Advanced healthcare materials","studyType":"Clinical Study"},{"pmid":"34423724","year":"2022","title":"Nebulization with alkaline hipertonic ibuprofen induces a rapid increase in platelets circulating in COVID-19 patients but not in healthy subjects.","finding":"","journal":"Platelets","studyType":"Clinical Study"},{"pmid":"27965129","year":"2017","title":"Comparative subcutaneous repeated toxicity study of enoxaparin products in rats.","finding":"","journal":"Regulatory toxicology and pharmacology : RTP","studyType":"Clinical Study"},{"pmid":"26023170","year":"2015","title":"Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.","finding":"","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","studyType":"Clinical Study"},{"pmid":"18480673","year":"2008","title":"In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.","finding":"","journal":"Coronary artery disease","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Les Laboratoires des Médicaments Stériles","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Bleeding","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevation of serum aminotransferase","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Ecchymosis","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Confusion","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site hematomas","drugRate":"9%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Major bleeding (Abdominal Surgery)","drugRate":"4%","severity":"serious"},{"effect":"Major bleeding (Colorectal Surgery)","drugRate":"4%","severity":"serious"},{"effect":"Major bleeding (Hip Replacement Surgery without Extended Prophylaxis)","drugRate":"4%","severity":"serious"},{"effect":"Major bleeding (Knee Replacement Surgery without Extended Prophylaxis)","drugRate":"1%","severity":"serious"},{"effect":"Major bleeding (Medical Patients during Acute Illness - 40mg daily)","drugRate":"0.8%","severity":"serious"},{"effect":"Major bleeding (Treatment of DVT and PE - 1.5mg/kg daily)","drugRate":"2%","severity":"serious"},{"effect":"Major bleeding (Treatment of DVT and PE - 1mg/kg q12h)","drugRate":"2%","severity":"serious"},{"effect":"Hemorrhage","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Les Laboratoires des Médicaments Stériles","patents":[],"pricing":[],"allNames":["enoxa®"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase","modality":"Small Molecule","explanation":"Unfortunately, there is not enough information available to explain how Enoxap works in simple terms. Typically, small molecule drugs work by interacting with specific biological targets, such as proteins or receptors, to produce a desired effect. However, without more information, it is impossible to provide a clear explanation of Enoxap's mechanism of action.","oneSentence":"Enoxa is a small molecule drug, but its exact mechanism of action is unknown.","technicalDetail":"As a small molecule drug, Enoxap's mechanism of action would typically involve binding to a specific biological target, such as a protein or receptor, to produce a pharmacological effect. However, without more information on its target and drug class, it is impossible to provide a detailed technical explanation of its mechanism of action."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=enoxa%C2%AE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=enoxa®","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:27:39.803214","biosimilars":[],"competitors":[],"genericName":"enoxa®","indications":{"approved":[{"name":"Acute gonococcal cervicitis","diseaseId":"acute-gonococcal-cervicitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal urethritis","diseaseId":"acute-gonococcal-urethritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea","diseaseId":"gonorrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea of pharynx","diseaseId":"gonorrhea-of-pharynx","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea of rectum","diseaseId":"gonorrhea-of-rectum","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infectious disease","diseaseId":"urinary-tract-infectious-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02444572","phase":"PHASE4","title":"Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®","status":"COMPLETED","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2015-10","conditions":["Gastrointestinal Neoplasms","Thromboembolic Event"],"enrollment":168,"completionDate":"2020-07-10"},{"nctId":"NCT01687491","phase":"PHASE4","title":"Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2012-07","conditions":["Acute Coronary Syndrome","Factor X"],"enrollment":179,"completionDate":"2014-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Les Laboratoires des Médicaments Stériles","relationship":"Original Developer"}],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"Les Laboratoires des Médicaments Stériles","recentPublications":[{"date":"2025 Oct","pmid":"39757753","title":"Polycationic γ-Cyclodextrin with Amino Side Chains for a Highly Efficient Anti-Heparin Coagulant.","journal":"Advanced healthcare materials"},{"date":"2022 Apr 3","pmid":"34423724","title":"Nebulization with alkaline hipertonic ibuprofen induces a rapid increase in platelets circulating in COVID-19 patients but not in healthy subjects.","journal":"Platelets"},{"date":"2017 Mar","pmid":"27965129","title":"Comparative subcutaneous repeated toxicity study of enoxaparin products in rats.","journal":"Regulatory toxicology and pharmacology : RTP"},{"date":"2015 Nov","pmid":"26023170","title":"Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis"},{"date":"2008 Jun","pmid":"18480673","title":"In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.","journal":"Coronary artery disease"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ENOXA®","companyName":"Les Laboratoires des Médicaments Stériles","companyId":"les-laboratoires-des-m-dicaments-st-riles","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxa is a small molecule drug developed by Les Laboratoires des Médicaments Stériles, with its current ownership status remaining unchanged. Unfortunately, there is limited information available on its target, drug class, and approved indications. As a result, its commercial status, key safety considerations, and other essential details remain unknown. Further research is necessary to understand the specifics of Enoxap. The lack of available information makes it challenging to provide a comprehensive summary.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}